Related Experiment Video
Updated: May 5, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Estimated burden of fungal infections in Panama
Cristel Rodríguez-Vargas1, Ana Alastruey-Izquierdo2, David W Denning3
1Department of Infectious Diseases Hospital Santo Tomás, Panama.
Abstract:
Data published on Panamanian fungal disease are scarce, mostly case reports. To date, there is no paper that compiles the burden of fungal disease Here we estimate for the first time the incidence and prevalence of fungal diseases in Panama. Data on fungal disease were obtained from different search engines: PubMed, Google Scholar, Scielo and Lilacs. For population and at risk diseases, we used statistics from worldometer, UNAIDS, and WHO. Incidence, prevalence, and absolute numbers were calculated based on the population at risk. Panamanian population in 2022 was 4,429,739. We estimated that 85,530 (1.93 %) people suffer from fungal diseases. The most frequent fungal infection was recurrent Candida vaginitis (3285/100,000). There are 31,000 HIV-infected people in Panama and based on the number of cases not receiving anti-retroviral therapy (14,570), and previous reports of prevalence of opportunistic infections, we estimated annual incidences of 4.0/100,000 for cryptococcal meningitis, 29.5/100,000 for oral candidiasis, 23.1/100,000 for esophageal candidiasis, 29.5/100,000 for Pneumocystis pneumonia, 15.1/100,000, and for histoplasmosis. For chronic pulmonary aspergillosis (CPA) and fungal asthma we used data from Guatemala and Colombia to estimate COPD and asthma prevalence and WHO report for tuberculosis. We estimated annual incidences of 6.1/100,000 for invasive aspergillosis and prevalence of 31.5/100,000 for CPA, 60.2/100,000 for allergic bronchopulmonary aspergillosis, and 79.5/100,000 for severe asthma with fungal sensitisation. Other incidence estimates were 5.0/100,000 for candidaemia, 0.20/100,000 for mucormycosis, and 4.97/100,000 for fungal keratitis. Even though this report on burden of fungal disease is a forward step, more epidemiological studies to validate these estimates are needed.
Insights
This study estimates the burden of fungal diseases in Panama, finding 1.93% of the population affected. Recurrent Candida vaginitis is the most common fungal infection, with significant incidence of other serious fungal conditions.
Area of Science:
- Medical Mycology
- Infectious Diseases Epidemiology
- Public Health
Background:
- Fungal disease data in Panama is limited, primarily consisting of case reports.
- A comprehensive understanding of the fungal disease burden in Panama is lacking.
- This study addresses the need for epidemiological data on fungal infections in the region.
Purpose of the Study:
- To estimate the incidence and prevalence of fungal diseases in Panama for the first time.
- To quantify the burden of various fungal infections within the Panamanian population.
- To provide baseline data for public health interventions and future research.
Main Methods:
- Data compilation from PubMed, Google Scholar, Scielo, and Lilacs for fungal diseases.
- Utilization of population statistics from worldometer, UNAIDS, and WHO for at-risk populations.
- Calculation of incidence, prevalence, and absolute numbers based on Panamanian population data (4,429,739 in 2022).
Main Results:
- An estimated 1.93% (85,530 individuals) of the Panamanian population suffers from fungal diseases.
- Recurrent Candida vaginitis is the most frequent infection (3285/100,000).
- Estimated incidences include cryptococcal meningitis (4.0/100,000), invasive aspergillosis (6.1/100,000), and candidaemia (5.0/100,000).
Conclusions:
- This study provides the first estimates of fungal disease burden in Panama.
- The findings highlight the significant prevalence of fungal infections, including common and opportunistic types.
- Further epidemiological studies are recommended to validate these estimates and inform public health strategies.
Related Concept Videos
Fungal Phylum Microsporidia
Antifungal Agents

